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Abstract
Purpose Radiolabelled glucagon-like peptide 1 (GLP-1) re-
ceptor agonists have recently been shown to successfully
image benign insulinomas in patients. For the somatostatin
receptor targeting of tumours, however, it was recently report-
ed that antagonist tracers were superior to agonist tracers. The
present study therefore evaluated various forms of the 125io-
dinated-Bolton-Hunter (BH)-exendin(9–39) antagonist tracer
for the in vitro visualization of GLP-1 receptor-expressing
tissues in rats and humans and compared it with the agonist
tracer 125I-GLP-1(7–36)amide.
Methods Receptor autoradiography studies with 125I-GLP-
1(7–36)amide agonist or 125I-BH-exendin(9–39) antagonist
radioligands were performed in human and rat tissues.
Results The antagonist 125I-BH-exendin(9–39) labelled at ly-
sine 19 identifies all human and rat GLP-1 target tissues and
GLP-1 receptor-expressing tumours. Binding is of high affin-
ity and is comparable in all tested tissues in its binding
properties with the agonist tracer 125I-GLP-1(7–36)amide.
For comparison, 125I-BH-exendin(9–39) with the BH labelled
at lysine 4 did identify the GLP-1 receptor in rat tissues but not
in human tissues.
Conclusion The GLP-1 receptor antagonist exendin(9–39)
labelled with 125I-BH at lysine 19 is an excellent GLP-1
radioligand that identifies human and rat GLP-1 receptors in
normal and tumoural tissues. It may therefore be the molecular
basis to develop suitable GLP-1 receptor antagonist
radioligands for in vivo imaging of GLP-1 receptor-
expressing tissues in patients.
Keywords Human tumours . GLP-1 receptors . Exendin(9–39)
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Introduction
The receptors for the gut hormone glucagon-like peptide 1
(GLP-1) are physiologically expressed in the endocrine pan-
creas as well as in very large quantities in specific endocrine
tumours such as benign insulinomas [1–3]. These receptors
have great clinical importance. Indeed, on the one hand, they
mediate the action of commercially available GLP-1 ana-
logues such as exenatide or liraglutide to help treat diabetes
patients by stimulating their insulin release [4, 5]. On the other
hand, they can be targeted to visualize insulinoma tumours
in vivo [6–11]. Available GLP-1-derived drugs for diabetes
therapy as well as for insulinoma imaging are agonists.
Indeed, for diabetes therapy, the compounds need to efficient-
ly stimulate insulin release, as is also the case with natural
GLP-1 [4, 5]. For imaging, current radiolabelled GLP-1 ana-
logues are, thanks to their agonistic characteristics, massively
internalized into the tumour cells, providing, as a conse-
quence, a strong imaging signal from the tumour site [12].
This agonist-induced receptor internalization has been shown
to be a general feature, not only for GLP-1 analogues, but also
for somatostatin, gastrin-releasing peptide (GRP) or cholecys-
tokinin (CCK) [13]. Recently, however, it has been shown in
the somatostatin receptor and GRP receptor field that
radioligand antagonists, even though they do not internalize,
can represent equally good or even better imaging agents
[14–16]. Since potent GLP-1 receptor antagonists have been
reported [17], it is worth asking whether radiolabelled GLP-1
receptor antagonists may be of use for GLP-1 receptor imag-
ing. While the [Lys40(111In-diethylenetriaminepentaacetic ac-
id)]-exendin(9–39) antagonist was found unsuitable for
in vivo targeting of GLP-1 receptor tissues [12], another
radioligand, the 125I-Bolton-Hunter (BH)-labelled
exendin(9–39) antagonist was shown to successfully label
pancreatic islets in rats ex vivo [18]. Subsequent work with
this radioligand seemed, however, to suggest that the com-
pound was species dependent, with good affinity to rat GLP-1
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receptors, but less affinity to humanGLP-1 receptors, possibly
jeopardizing in vivo imaging of insulinomas in humans [19].
Based on the fact that BH labelling may result in targeting
different amino residues of a peptide depending on the label-
ling conditions, we re-evaluated the binding of the BH-
labelled GLP-1 receptor antagonist with receptor autoradiog-
raphy in vitro and found that the BH labelling site is important
to obtain a GLP-1 receptor antagonist radioligand binding
with high affinity to human GLP-1 receptors expressed in
insulinoma and endocrine pancreas.
Materials and methods
Tissues
The tissues used were human tumours and human non-
neoplastic tissues representingGLP-1 targets, such as endocrine
pancreas or duodenal Brunner’s glands (see Tables 3 and 4).
These tissues, already used in previous studies [2, 19], were
collected in accordance with international ethical guidelines,
including informed consent and approval by the Institutional
Review Board. For control and comparison purposes, we also
used normal rat pancreatic, duodenal, lung and thyroid tissues,
as reported previously (see Table 3) [2].
Tracers
(1) The GLP-1 receptor agonist 125I-GLP-1(7–36)amide was
labelled byCelerion SwitzerlandAG (Fehraltorf, Switzerland)
and purchased at ANAWA Trading SA (Wangen,
1
2
3 4
Fig. 1 HPLC of 125I-BH-exendin(9–39) showing the various radioactive
peaks 1–4. Specific binding was obtained in peaks 2 and 4. Peaks 1 and 3
did not bind. Peak 1 represents labelled BH
Table 1 Binding affinities (IC50) for GLP-1(7–36)amide agonist and
exendin(9–39) antagonist in binding assays using 125I-GLP-1(7–36)am-
ide and 125I-BH-exendin(9–39) (peaks 2 and 4) as radioligands. Tissue:
human insulinoma
Tracer Binding affinity IC50
(nM) mean ± SEM, n≥3
Competitor
GLP-1(7–36)
amide
Exendin
(9–39)
125I-GLP-1(7–36)amide 3.1±0.4a 63±47a
125I-BH-exendin(9–39) ANAWA peak 2
antagonist
No binding No binding
125I-BH-exendin(9–39) ANAWA peak 4
antagonist
1.9±0.6 13±1.7
a Published in [19]
Table 2 GLP-1 receptor density (dpm/mg tissue, mean ± SEM, n=3) in
human pancreatic islets and insulinoma: comparison of different tracers
Tracer Human pancreatic
islets
Human
insulinoma
125I-BH-exendin(9–39) ANAWA
peak 2 antagonist
No binding No binding
125I-BH-exendin(9–39) ANAWA
peak 4 antagonist
1,696±418 8,093±1,344
125I-BH-exendin(9–39) PerkinElmer
antagonist
1,925±696 7,472±1,061
125I-GLP-1(7–36)amide agonist 1,760±159 7,585±1,253
dpm/mg disintegrations per minute per milligram
Table 3 Comparison of the GLP-1 receptor density in various types
of GLP-1 receptor-positive normal tissues using the radiolabelled
GLP-1(7–36)amide agonist and ANAWA peak 4 antagonist
Normal tissues GLP-1 receptor density (dpm/mg
tissue, mean ± SEM)
125I-GLP-1
(7–36)amide
agonist tracer
125I-BH-exendin (9–39)
antagonist tracer
(ANAWA peak 4)
Human
Pancreas, n=5
Islets 1,482±192 1,470±313
Acini 225±91a 369±110
Pancreatic ducts – –
Brunner’s glands, n=4 2,917±582 2,992±530
Neurohypophysis, n=3 5,274±805 5,583±799
Leptomeninx, n=3 1,597±495 1,735±355
Colon (plexus myentericus), n=3 1,056±34 753±208
Thyroid, n=3 – –
Lung, n=3
Parenchyma – –
Vessels 893±84 588±148
Rat
Pancreas, n=3
Islets 4,643±207 4,446±588
Acini 155b –
Brunner’s glands, n=3 >10,000 >10,000
Lung (parenchyma), n=3 7,562±124 7,343±239
Thyroid, n=3 2,886±767 2,530±407
dpm/mg disintegrations per minute per milligram
a 2 of the 5 samples had acini with undetectable levels of GLP-1 receptor
b 2 of the 3 samples had acini with undetectable levels of GLP-1 receptor
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Switzerland). 125I-GLP-1(7–36)amide was used as reported
before [2]. (2) The GLP-1 receptor antagonist exendin(9–39)
was labelled by Celerion Switzerland AG and purchased at
ANAWATrading SA. It was labelled with 125I-BH and differ-
ent labelling products were separated by HPLC. The various
HPLC peaks obtained were then analysed for binding with
autoradiography. Non-radioactive BH-exendin(9–39) was ob-
tained by modification of exendin(9–39) with 3-(4-
hydroxyphenyl)propionic acid N-hydroxysuccinimide ester.
Products were separated by HPLC. (3) A commercially avail-
able 125I-BH-exendin(9–39) antagonist was purchased from
PerkinElmer.
Autoradiography
Autoradiography was performed as reported previously [2,
19], using each of the above-mentioned radioligands, under
identical experimental conditions. Briefly, 20 μm thick frozen
tissue sections were incubated for 2 h at room temperature in
the incubation solution containing 170 mM Tris-HCl buffer
(pH 8.2), 1 % bovine serum albumin (BSA), 40 μg/ml baci-
tracin, 10 mM MgCl2 and 15,000 cpm/100 μl of tracer. Non-
specific binding was determined by incubating tissue sections
in the incubation solution containing, additionally, 100 nM
unlabelled cold GLP-1(7–36)amide (Bachem, Bubendorf,
Switzerland). Further pharmacological displacement experi-
ments were performed to measure IC50 values using increas-
ing concentrations of the GLP-1 receptor agonist and antago-
nist. After incubation, the slides were washed five times in ice-
cold Tris-HCl buffer (170 mM, pH 8.2) containing 0.25 %
BSA and twice in ice-cold Tris-HCl buffer without BSA. The
slides were dried for 15 min under a stream of cold air and
then exposed to Kodak BioMaxMR® films for 7 days at 4 °C.
The signals on the films were analysed in correlation with
morphology using corresponding tissue slides stained with
haematoxylin and eosin (H&E). The receptor density was
quantitatively assessed using tissue standards for iodinated
compounds (Amersham, Aylesbury, UK) and a computer-
assisted image processing system (Analysis Imaging System,
Interfocus, Mering, Germany) [3].
Results
Radioligand characteristics
For the antagonist radioligand 125I-BH-exendin(9–39)
(ANAWA), HPLC separated several peaks that were subse-
quently analysed by receptor autoradiography for binding
(Fig. 1). Peak 1 (corresponding to the labelled BH reagent)
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Fig. 2 GLP-1 receptor autoradiography in rat (left panels) and human
(right panels) pancreatic islets using the antagonist tracer 125I-BH-
exendin(9–39) ANAWA peak 4 (upper row) or the agonist tracer 125I-
GLP-1(7–36)amide (lower row). Each set represents H&E staining (left),
total binding (middle) and non-specific binding (right). Bars=1 mm. The
rat islets have much more receptors than human islets
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rat humanFig. 3 GLP-1 receptor
autoradiography in rat (left
panels) and human (right panels)
duodenal Brunner’s gland, using
the antagonist tracer 125I-BH-
exendin(9–39) ANAWA peak 4
(upper row) or the agonist tracer
125I-GLP-1(7–36)amide (lower
row). Each set represents H&E
staining (left), total binding
(middle) and non-specific binding
(right). Bars=1 mm
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and peak 3 did not bind the GLP-1 receptor. While peaks 2
and 4 bound with high affinity to the rat GLP-1 receptor, it
was found that peak 2 did not bind to human tissue (Table 1).
Conversely, peak 4 bound with high affinity to human tissue;
IC50 in human insulinoma for GLP-1(7–36)amide was 1.9±
0.6 nM and for exendin(9–39) 13±1.7 nM. For comparison,
the radiolabelled GLP-1 agonist bound to human insulinoma
with high affinity as well: IC50 for GLP-1(7–36)amide was
3.1±0.4 nM and for exendin(9–39) 63±47 nM (Table 1).
Table 2 shows the density values in human pancreatic islets
and human insulinomas using four different tracers: 125I-BH-
exendin(9–39) antagonist ANAWA peaks 2 and 4, commer-
cially available 125I-BH-exendin(9–39) antagonist tracer from
PerkinElmer and 125I-GLP-1(7–36)amide agonist. While
ANAWA peak 2 antagonist was negative in these human
tissues, ANAWA peak 4 antagonist showed GLP-1 receptor
expression in both tissues, with density values comparable to
those obtained with the PerkinElmer antagonist tracer and
with the GLP-1(7–36)amide agonist tracer (Table 2).
In order to identify the exact sites of BH labelling in
exendin(9–39), the peptide was labelled with non-iodinated
BH reagent by Celerion Switzerland AG and processed for
matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry by the ETH Zurich. It showed that BH labelling
in peak 2 occurs only on lysine in position 4, while BH
labelling in peak 4 is predominantly on the lysine in position
19 and, to a lower extent, on lysine in position 4. Therefore,
high-affinity binding of peak 4 to human tissues is likely due
to the BH labelling at lysine 19.
Table 3 compares the GLP-1 receptor density in various
types of GLP-1 receptor-positive normal tissues using the
radiolabelled GLP-1(7–36)amide agonist and ANAWA peak
4 antagonist. It basically shows that similar values are obtain-
ed with both tracers in normal pancreatic tissues, in both
humans and rats (Fig. 2). It is worth noting that the rat islets
have more GLP-1 receptors than human islets, an observation
that is found with both agonist and antagonist tracers; further,
the ratio of receptor density between islets and acini is much
higher in rats than in humans (Fig. 2). Finally, both tracers
show similar receptor densities in other tissues including
Brunner’s glands (Fig. 3), neurohypophysis, leptomeninx,
plexus myentericus of the colon and lung vessels (Table 3).
The human lung parenchyma and thyroid are receptor nega-
tive with both tracers, while the respective rat tissues have a
high density of receptors with both tracers (Fig. 4).
Table 4 shows that both tracers detect similar numbers of
GLP-1 receptors in human neuroendocrine and brain tumours.
As representative example, Fig. 5 shows GLP-1 receptor
autoradiography of an insulinoma, a medullary thyroid carci-
noma and a phaeochromocytoma.
Figure 6 is a complete displacement curve in a human
insulinoma using ANAWA peak 4 antagonist; it shows the
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Fig. 4 GLP-1 receptor
autoradiography in rat (left
panels) and human (right panels)
lung and thyroid using the 125I-
BH-exendin(9–39) ANAWA
peak 4 antagonist. Each set
represents H&E staining (left),
total binding (middle) and non-
specific binding (right). Bars=
1 mm
Table 4 Detection of GLP-1 receptors in human neuroendocrine and brain tumours
Human tumours 125I-GLP-1(7–36)amide agonist tracer 125I-BH-exendin(9–39) antagonist tracer (ANAWA peak 4)
Incidence of GLP-1
receptor-positive
tumours
Receptor density, dpm/mg
tissue (mean±SEM)
Incidence of GLP-1
receptor-positive
tumours
Receptor density, dpm/mg
tissue (mean±SEM)
Insulinomas, n=5 5/5 8,575±1,386 5/5 9,455±1,715
Medullary thyroid carcinomas, n=3 3/3 1,455±557 3/3 1,376±558
Phaeochromocytomas, n=6 5/6 2,593±355 5/6 2,369±411
Paragangliomas, n=5 2/5 1,380±34 2/5 1,332±36
Meningiomas, n=7 4/7 858±203 4/7 498±196
dpm/mg disintegrations per minute per milligram
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high affinity displacement by GLP-1(7–36)amide and lower
affinity displacement by exendin(9–39), while the unrelated
peptide somatostatin 28 is inactive.
Discussion
Following the recent advances in the somatostatin and
bombesin receptor field, documenting that radiolabelled an-
tagonists may be as good or better than agonists for tumour
labelling in animals and tumour patients [14, 20], we demon-
strate here that a radiolabelled GLP-1 receptor antagonist is
able to detect human GLP-1 receptors with high affinity. It
also reveals the importance of the BH labelling site of the
exendin(9–39) antagonist. Indeed, BH labelling on lysine 19
(ANAWA peak 4) provides a radioligand that is able to detect
with similar affinities rat and human GLP-1 receptors, while
BH labelling on lysine 4 (ANAWA peak 2) only permits
detection of rat GLP-1 receptors.
Our comparative in vivo study shows that both a GLP-1
receptor agonist tracer and a GLP-1 receptor antagonist tracer
(with BH labelling on lysine in position 19) are able to label a
comparable number of GLP-1 receptors in a large variety of
normal and tumoural tissues. This indicates that radiolabelled
GLP-1 receptor antagonists could have the potential to be-
come successful GLP-1 receptor markers, in particular for
certain human cancers. In the present study, we can further
state that the previously observed species difference in GLP-1
receptor expression in rat and human thyroid and lung shown
with a GLP-1 agonist [2] is also observed with the GLP-1
receptor antagonist ligand and is therefore a finding indepen-
dent of the chosen tracers. Of further major interest is the
observation of the difference in GLP-1 receptor expression
between rat and human pancreatic islets. The rat islets express
much more GLP-1 receptors than human islets. Moreover, the
rat acini express usually fewer (often even undetectable levels)
of the GLP-1 receptors than the human acini, providing an islet
to acini ratio of the GLP-1 receptors much higher in rats than
in human. This suggests that it could become more difficult to
label beta cells in vivo in humans than in rats [18, 21].
Interestingly, we do not find a markedly higher amount of
labelled GLP-1 receptors with the antagonist tracer compared
to the agonist tracer. This is different from recently shown data
obtained with somatostatin receptors, where a much larger
number of receptors was labelled by a radiolabelled sst2
antagonist than by an agonist, using a similar experimental
set-up [22]. At present, the exact reasons (numbers of binding
sites, dissociation rate, metabolic stability) why antagonists
behave so well in vivo in imaging studies (somatostatin re-
ceptor, GRP receptor) are still under debate and will need
extensive future investigations. For the moment, the fact that
labelling of GLP-1-expressing tumours with the antagonist is
excellent provides the chance to develop GLP-1 receptor
antagonists for tumour imaging and therapy.
Antagonist compounds may have less side effects than
agonists, as observed with radiolabelled GRP receptor ana-
logues [23]. As it is known that GLP-1 receptor agonists used
for insulinoma imaging can frequently induce a transient
hypoglycaemic effect [6, 11], it would therefore be an advan-
tage to use radiolabelled GLP-1 receptor antagonists that do
not have this unwanted side effect.
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Fig. 5 GLP-1 receptor autoradiography in a human insulinoma, a med-
ullary thyroid carcinoma and a phaeochromocytoma using the antagonist
tracer 125I-BH-exendin(9–39) ANAWA peak 4 or agonist tracer 125I-
GLP-1(7–36)amide. Each row shows from left to right: H&E staining
(bars=1 mm), total binding of antagonist, non-specific binding of antag-
onist, total binding of agonist and non-specific binding of agonist
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Fig. 6 Displacement curve of 125I-BH-exendin(9–39) ANAWA peak 4
antagonist by GLP-1(7–36), exendin(9–39) and somatostatin 28 (SS-28).
Mean of n=3 experiments
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